Try our beta test site
Trial record 2 of 8 for:    progeria

Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2015 by Boston Children’s Hospital
Information provided by (Responsible Party):
Monica E. Kleinman, Children's Hospital Boston Identifier:
First received: October 13, 2015
Last updated: December 23, 2015
Last verified: December 2015
This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utilizing the Clinical and Translational Study Unit (CTSU) at Boston Children's Hospital. Lonafarnib will be administered at doses previously established in the pediatric population and in this population of progeria subjects. This study will first determine the dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) of everolimus when administered in combination with lonafarnib. It will then determine the efficacy of everolimus when administered at its MTD in combination with lonafarnib for disease in progeria.

Condition Intervention Phase
Drug: Everolimus and lonafarnib
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

Resource links provided by NLM:

Further study details as provided by Boston Children’s Hospital:

Primary Outcome Measures:
  • Maximum-tolerated dose (MTD) of everolimus when administered orally in combination with lonafarnib in subjects with progeria [ Time Frame: 12 Months ]
    For Phase I portion of protocol

  • Number and type of dose-limiting toxicities when everolimus and lonafarnib are administered in combination to children with progeria [ Time Frame: 12 Months ]
    For Phase I portion of protocol

  • Annual increase in weight gain [ Time Frame: 24 Months ]
    For Phase II portion of protocol

  • Change in pulse wave velocity (PWV) [ Time Frame: 24 months ]
    For Phase II portion of protocol

Secondary Outcome Measures:
  • Markers of progeria-specific activity [ Time Frame: 24 Months ]
    For Phase II portion of protocol

  • Trough levels of everolimus in combination with lonafarnib in progeria [ Time Frame: 12 months ]
    For Phase I portion of protocol

Estimated Enrollment: 80
Study Start Date: December 2015
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Everolimus and Lonafarnib
Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
Drug: Everolimus and lonafarnib


Ages Eligible for Study:   18 Months to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Genetically-confirmed progeria.
  • display clinical signs of progeria as per the clinical trial team.
  • currently receiving lonafarnib under protocol 09-06-0298
  • have not experienced a grade 3 or 4 toxicity within two months preceding enrollment
  • willing and able to come to Boston for appropriate studies and examinations.
  • no recent fractures or major surgery (within four weeks)
  • Absolute poly count (Absolute neutrophil count + bands + monocytes) >1,000/uL
  • platelets >75,000/uL (transfusion independent)
  • hemoglobin >9 g/dL
  • creatinine ≤ 1.5 times upper limit of normal (ULN) for age or Glomerular filtration rate (GFR) >70 mL/min/1.73m2
  • bilirubin ≤ 1.5x upper limit of normal for age
  • SGPT (ALT) < and SGOT (AST) ≤ 2.5x normal range for age
  • serum albumin greater than or equal to 2 g/dL
  • PT/PTT: INR <1.3 (or <3 on anticoagulants)
  • Fasting LDL cholesterol within 1.5x ULN per institutional guidelines (ie, <195 mg/dL for 2 - 18 years of age, <240 mg/dL for subjects >18 years old)* and Fasting serum cholesterol <300 mg/dL (<7.75 mmol/L)* and Fasting triglycerides <2.5 ULN (<325 mg/dL for ages 2 - 18, <400 for ages >18)*

    *may be re-evaluated for eligibility after initiation of lipid-lowering therapy

  • Signed informed consent according to institutional guidelines must be obtained and subject must begin therapy within twenty-eight (28) days.

Exclusion Criteria:

  • Other than the drugs used in this protocol, other drugs targeted to treat progeria are excluded. Drugs to treat symptoms of progeria are permitted.
  • Subjects must not be taking medications that significantly affect the metabolism of lonafarnib
  • Subjects receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Subjects with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. Topical or inhaled steroids are allowed.
  • Subjects who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug; have not recovered from the side effects of any major surgery (defined as requiring general anesthesia but excluding a procedure for insertion of central venous access); or who may require major surgery during the course of the study.
  • 13.2.5 Subjects with an active bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin).
  • Subjects who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

    • known severely impaired lung function
    • active (acute or chronic) or uncontrolled severe infections.
    • liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
    • History of hepatitis B or hepatitis C
  • Other concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration).
  • A known history of Human Immunodeficiency Virus (HIV) seropositivity or known immunodeficiency.
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). A nasogastric tube (NG tube) or gastric tube (G tube) is allowed.
  • Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated.
  • Subjects must not be pregnant or breast-feeding. Female subjects of childbearing potential must have negative serum or urine pregnancy test. Sexually active male and female subjects of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment. It is permissible for female subjects to take oral contraceptives or other hormonal methods while receiving treatment with everolimus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02579044

Contact: Monica Kleinman, M.D. (617)-355-7327
Contact: Nathalie Fadel, B.S. (617)-355-6899

United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States
Contact: Monica E Kleinman, MD   
Sponsors and Collaborators
Boston Children’s Hospital
Principal Investigator: Monica Kleinman, M.D. Boston Children’s Hospital
  More Information

Responsible Party: Monica E. Kleinman, Medical Director, Transport & MSICU, Children's Hospital Boston Identifier: NCT02579044     History of Changes
Other Study ID Numbers: P00017505
Study First Received: October 13, 2015
Last Updated: December 23, 2015

Additional relevant MeSH terms:
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on March 30, 2017